GeneDx, a leading biopharma stock specializing in genome and exome sequencing, has seen a staggering 2,600% return in 2024.
The top mid-cap stock of 2024, GeneDx, has returned more than 2,600%. While large caps and small caps get more attention, mid cap stocks have quietly been the best performers over the long term. Over the last 25 years dating back to 1999, mid-caps have beaten both large and small-cap stocks, although large caps have slightly better performance in the 20-year and 10-year windows. Mid-cap stocks have also been the best over the past 30 years.
has returned nearly 24%, but mid-caps as measured by the S&P 400 have been solid, up 12% as of December 18. Mid-cap stocks, which generally range in market cap from $2 billion to $10 billion, are typically more volatile than large caps, with a wider range of performance. You can certainly see that at the top, as the top 5 mid-cap stocks of 2024 posted some huge returns. is a biopharma stock that specializes in genome and exome testing, diagnostics, and sequencing. It started the year trading at just under $3 per share and right now it is up to around $75 per share, a ridiculous 2,650% increase year-to-date. GeneDx used to be called Sema4, which acquired GeneDX in 2022. It took the GeneDX name, as the company specialized in the growing field of genome and exome sequencing and diagnostics. GeneDx soon became one of the leaders in the field, particularly in exome sequencing, which helps doctors understand what is causing symptoms or disease in a patient. GeneDx has sequenced more than 500,000 clinical exomes and has an 80% market share among ordering clinicians. In the most recent quarter, it grew revenue by 77%, reported adjusted gross margins of 64%, and reached profitability for the first time, with adjusted net income of $1.2 million. It also raised its fiscal 2024 revenue guidance. Given the meteoric rise, investors should be a little wary, at least in the near-term. Recently, some of the executives sold shares. But still, GeneDx looks to have a bright futur
GENEDX STOCK MARKET MID-CAP BIO-PHARMA GENOME SEQUENCING
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bill Skarsgård's Rotten Tomatoes Cold Streak Is Officially Over Thanks To Acclaimed Upcoming Horror MovieBill Skarsgard in the posters for The Crow (2024), Boy Kills World (2024), and Nosferatu (2024)
Read more »
Mid Cap Stocks Soar in 2024, Led by GeneDx's Explosive GrowthMid cap stocks are outperforming their larger and smaller counterparts in 2024, with the S&P 400 up 12% year-to-date. GeneDx, a leading provider of genome and exome sequencing diagnostics, has been the standout performer, surging over 2,600% in value.
Read more »
iPad Mini (2024) vs iPad Air (2024): Which One is Right for You?Apple's 2024 iPad lineup includes a refreshed iPad mini and a new iPad Air with two screen sizes. This comparison helps you decide between these two popular models.
Read more »
See How and What You Photographed in 2024 With Google Photos’ 2024 RecapGoogle Photos' new AI-powered year-in-review, 2024 Recap, shows users how and what they photographed in 2024.
Read more »
Taylor Swift, Drake, Sabrina Carpenter & More Top Billboard’s Top 10 Artists of 2024Taylor Swift, Sabrina Carpenter, Zach Bryan and more fill up the remaining five spots in Billboard’s Top 10 Artists of 2024. With hits dominating the Hot 100 throughout 2024 along with albums that have reigned the Billboard 200, each artist has earned their well-deserved slot.
Read more »
Morgan Wallen Accepts Top Male Artist, Top Country Artist, Top Country Male Artist & Top CollaborationMorgan Wallen accepts Top Male Artist, Top Country Artist, Top Country Male Artist and Top Collaboration at the 2024 Billboard Music Awards.
Read more »